Q2 FY2025 · ended Jun 30, 2025 · Revenue $13.68M, -89.3% YoY · Filed Aug 13, 2025
Adaptimmune Therapeutics PLC (ADAPY) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2025, the quarter ended Jun 30, 2025, it reported revenue of $13.7 million and a net loss of $30.3 million. Free cash flow was -$34.9 million. As of Jun 30, 2025 it held $26.1 million in cash and investments and $48.7 million in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ADAPY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Abingdon, Oxfordshire
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1621227
- Former names
- Adaptimmune Ltd (until Mar 17, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2025 Jun 30, 2025 |
Q1 FY2025 Mar 31, 2025 |
Q4 FY2024 Dec 31, 2024 |
Q3 FY2024 Sep 30, 2024 |
Q2 FY2024 Jun 30, 2024 |
|---|---|---|---|---|---|
| Revenue | $13.7M | $7.3M | $3.2M | $40.9M | $128.2M |
| Operating income | -$30.3M | -$45.7M | -$73.5M | -$14.7M | $68.7M |
| Net income | -$30.3M | -$47.6M | -$74.2M | -$17.6M | $69.5M |
| Diluted EPS | -$0.02 | -$0.03 | -$0.05 | -$0.01 | $0.04 |
| Operating cash flow | -$34.8M | -$66.6M | -$34.2M | -$54.5M | $47.4M |
| Free cash flow | -$34.9M | -$67.8M | -$34.4M | -$54.6M | $47.0M |
| Total assets | $130.6M | $158.1M | $246.0M | $317.4M | $321.7M |
| Total liabilities | $201.6M | $195.5M | $234.1M | $237.4M | $225.4M |
| Stockholders' equity | -$71.0M | -$37.4M | $11.8M | $80.0M | $96.3M |
| Cash and investments | $26.1M | $59.6M | $151.6M | $186.1M | $214.8M |
| Total debt | $48.7M | $48.7M | $78.2M | $74.5M | $47.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Oct 20, 2025 | Oct 15, 2025 |
| 8-K |
Current report
Listing notice
|
Sep 26, 2025 | Sep 22, 2025 |
| 8-K |
Current report
Listing notice
|
Sep 12, 2025 | Sep 11, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 8, 2025 | Sep 6, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 29, 2025 | Aug 29, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 15, 2025 | Aug 15, 2025 |
All 808 Adaptimmune Therapeutics PLC SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.